Open AccessDRUG INTERACTIONS AMONG PATIENTS WITH HYPERTENSION TAKING ANGIOTENSINCONVERTING ENZYME INHIBITORS IN AN INDONESIAN HOSPITAL
Author(s) -
Santi Purna Sari,
Afi Fauziyah Darajat,
Binar Nursanti
Publication year - 2018
Publication title -
international journal of applied pharmaceutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.238
H-Index - 15
ISSN - 0975-7058
DOI - 10.22159/ijap.2018.v10s1.29
Subject(s) - polypharmacy , medicine , medical prescription , angiotensin converting enzyme , drug , mann–whitney u test , pathophysiology , pharmacology , blood pressure
Objective: This study aimed to analyze the drug interactions associated with angiotensin-converting enzyme (ACE) inhibitors for treating hypertensionat Karya Bhakti Pratiwi Hospital between July and December 2016.Methods: This was an analytical, descriptive, cross-sectional study based on the prescription and medical record data of hospitalized patients treatedwith an ACE inhibitor and one or more other drugs. Data were included by purposive sampling.Results: The final analysis was conducted with 120 prescriptions from 71 patients. We found that ACE inhibitors were associated with 139 potentialinteractions with other drugs in 75 prescriptions (53.96%); of these, 52 were major interactions and 87 were moderate interactions. The Mann–Whitney U-test confirmed that the potential drug interactions were significantly associated with polypharmacy (p 0.05). Finally, the Kruskal–Wallis test revealed no significant relationship betweenage and potential drug interactions (p>0.05).Conclusion: The final analysis was conducted with 120 prescriptions from 71 patients. We found that ACE inhibitors were associated with 139potential interactions with other drugs in 75 prescriptions (53.96%); of these, 52 were major interactions and 87 were moderate interactions. TheMann–Whitney U-test confirmed that the potential drug interactions were significantly associated with polypharmacy (p 0.05). Finally, the Kruskal–Wallis test revealed no significant relationshipbetween age and potential drug interactions (p>0.05).